The Chinese vaccine producer Sinopharm announced that an inactivated vaccine developed by its subsidiary China National Biotech Group (CNBG) has an efficacy rate of more than 79 percent, and confirmed that they have officially filed for market approval with the Chinese authority, a statement from the Chinese Embassy said.
Beijing Biological Products Institute under CNBG announced on its website on Wednesday that interim results of Phase-III clinical trials on an inactivated vaccine it developed showed that the vaccine can trigger high-titre Coronavirus antibodies after two injections.
The vaccine showed a 79. 34 percent efficacy and 99.52 percent antibody positive conversion rate, reaching the standards of the World Health Organization and Chinese authorities.
The institute said it had officially filed for market approval with the Chinese authority.
The CNBG Beijing Institute vaccine was said to be undergoing Phase-III clinical trials in more than ten foreign countries.
It was approved in the United Arab Emirates (UAE) and Bahrain earlier this month with an efficacy of 86 percent, according to the UAE Government. As a leading inactivated product, the Sinopharm’s vaccine could be kept in a standard home refrigerator at 2-8 degrees Celsius.